AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Conditions: Follicular Lymphoma; Mantle Cell Lymphoma; Hairy Cell Leukemia; Lymphoplasmacytic Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: CD22CART Infusion
Sponsors: Stanford University; The Leukemia and Lymphoma Society
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 4, 2024Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments